Institution
University of the Philippines
Education•Quezon City, Philippines•
About: University of the Philippines is a education organization based out in Quezon City, Philippines. It is known for research contribution in the topics: Population & Health care. The organization has 4589 authors who have published 4437 publications receiving 114846 citations. The organization is also known as: UP.
Topics: Population, Health care, Medicine, Adsorption, Public health
Papers published on a yearly basis
Papers
More filters
••
Paul Sabatier University1, Smithsonian Tropical Research Institute2, University of Minnesota3, University of Toronto4, Harvard University5, University of the Philippines6, Indian Institute of Science7, University of Peradeniya8, University of Missouri–St. Louis9, Field Museum of Natural History10, Florida State University11, Wildlife Conservation Society12, The Catholic University of America13, University of Georgia14, Osaka City University15, Thammasat University16, Nanyang Technological University17, Forest Research Institute Malaysia18, National Museum of Natural History19, University of Puerto Rico, Río Piedras20
TL;DR: The results do not support the hypothesis that fast-growing species are consistently increasing in dominance in tropical tree communities, and suggest that plots may be simultaneously recovering from past disturbances and affected by changes in resource availability.
Abstract: In Amazonian tropical forests, recent studies have reported increases in aboveground biomass and in primary productivity, as well as shifts in plant species composition favouring fast-growing species over slow-growing ones. This pervasive alteration of mature tropical forests was attributed to global environmental change, such as an increase in atmospheric CO2 concentration, nutrient deposition, temperature, drought frequency, and/or irradiance. We used standardized, repeated measurements of over 2 million trees in ten large (16–52 ha each) forest plots on three continents to evaluate the generality of these findings across tropical forests. Aboveground biomass increased at seven of our ten plots, significantly so at four plots, and showed a large decrease at a single plot. Carbon accumulation pooled across sites was significant (+0.24 MgC ha−1 y−1, 95% confidence intervals [0.07, 0.39] MgC ha−1 y−1), but lower than reported previously for Amazonia. At three sites for which we had data for multiple census intervals, we found no concerted increase in biomass gain, in conflict with the increased productivity hypothesis. Over all ten plots, the fastest-growing quartile of species gained biomass (+0.33 [0.09, 0.55] % y−1) compared with the tree community as a whole (+0.15 % y−1); however, this significant trend was due to a single plot. Biomass of slow-growing species increased significantly when calculated over all plots (+0.21 [0.02, 0.37] % y−1), and in half of our plots when calculated individually. Our results do not support the hypothesis that fast-growing species are consistently increasing in dominance in tropical tree communities. Instead, they suggest that our plots may be simultaneously recovering from past disturbances and affected by changes in resource availability. More long-term studies are necessary to clarify the contribution of global change to the functioning of tropical forests.
223 citations
••
01 Jan 2000
TL;DR: In this article, the authors used sediment cores to assess the health of an ecosystem and the degree to which it has been influenced by terrestrial and anthropogenic inputs using biomarkers such as lipid classes and fatty acids to determine production of marine biogenic material.
Abstract: Biomarkers are compounds or groups of compounds that can be used as signatures of individual organisms or groups of organisms, or of certain environmental processes Lipid and phenolic biomarkers can be used to assess the health of an ecosystem and the degree to which it has been influenced by terrestrial and anthropogenic inputs Lipid classes and fatty acids can be used to determine production of marine biogenic material of dietary value to pelagic and benthic organisms Polycyclic aromatic hydrocarbons and 5β-stanols such as coprostanol can be used to determine pollutant loading from oil spillage or sewage and the phenanthrene/methylphenanthrene ratio can be used specifically as an indicator of wood burning N-alkanes and thermochemolysis products in cores can show the sensitivity of sediments to changes in land use patterns near the land margin The relationship between marine and terrestrially derived products in sediment cores can be used to indicate the degree to which land use changes have impacted the pattern of marine biogenic productivity in the area Stable isotope and multivariate analyses are particularly useful for biomarker validation
222 citations
••
TL;DR: It is shown that no true advances have taken place in commercial eucheumatoid farming in over a decade and the capability to mitigate or eliminate pests, herbivores and diseases need to be addressed more closely.
222 citations
••
TL;DR: The results for gabapentin in terms of pain relief were conflicting, but combining the results favoured treatment group (gabapentin) over control group (placebo) over long-term results, based on adverse event data, while the results for calcitonin were variable.
Abstract: Background
This is an updated version of the original Cochrane review published in Issue 12, 2011. Phantom limb pain (PLP) is pain that arises in the missing limb after amputation and can be severe, intractable, and disabling. Various medications have been studied in the treatment of phantom pain. There is currently uncertainty in the optimal pharmacologic management of PLP.
Objectives
This review aimed to summarise the evidence of effectiveness of pharmacologic interventions in treating PLP.
Search methods
For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE, and Embase for relevant studies. We ran the searches for the original review in September 2011 and subsequent searches for this update up to April 2016. We sought additional studies from clinical trials databases and reference lists of retrieved papers.
Selection criteria
We included randomised and quasi-randomised trials studying the effectiveness of pharmacologic interventions compared with placebo, another active treatment, or no treatment, in established PLP. We considered the following outcomes: change in pain intensity, function, sleep, depression or mood, quality of life, adverse events, treatment satisfaction, and withdrawals from the study.
Data collection and analysis
We independently assessed issues of study quality and extracted efficacy and adverse event data. Due to the wide variability in the studies, we did not perform a meta-analysis for all the interventions and outcomes, but attempted to pool the results of some studies where possible. We prepared a qualitative description and narrative summary of results. We assessed clinical heterogeneity by making qualitative comparisons of the populations, interventions, outcomes/outcome measures, and methods.
Main results
We added only one new study with 14 participants to this updated review. We included a 14 studies (10 with low risk of bias and 4 with unclear risk of bias overall) with a total of 269 participants. We added another drug class, botulinum neurotoxins (BoNTs), in particular botulinum toxin A (BoNT/A), to the group of medications reviewed previously. Our primary outcome was change in pain intensity. Most studies did not report our secondary outcomes of sleep, depression or mood, quality of life, treatment satisfaction, or withdrawals from the study.
BoNT/A did not improve phantom limb pain intensity during the six months of follow-up compared with lidocaine/methylprednisolone.
Compared with placebo, morphine (oral and intravenous) was effective in decreasing pain intensity in the short term with reported adverse events being constipation, sedation, tiredness, dizziness, sweating, voiding difficulty, vertigo, itching, and respiratory problems.
The N-methyl D-aspartate (NMDA) receptor antagonists ketamine (versus placebo; versus calcitonin) and dextromethorphan (versus placebo), but not memantine, had analgesic effects. The adverse events of ketamine were more serious than placebo and calcitonin and included loss of consciousness, sedation, hallucinations, hearing and position impairment, and insobriety.
The results for gabapentin in terms of pain relief were conflicting, but combining the results favoured treatment group (gabapentin) over control group (placebo) (mean difference -1.16, 95% confidence interval -1.94 to -0.38; 2 studies). However, gabapentin did not improve function, depression score, or sleep quality. Adverse events experienced were somnolence, dizziness, headache, and nausea.
Compared with an active control benztropine mesylate, amitriptyline was not effective in PLP, with dry mouth and dizziness as the most frequent adverse events based on one study.
The findings for calcitonin (versus placebo; versus ketamine) and local anaesthetics (versus placebo) were variable. Adverse events of calcitonin were headache, vertigo, drowsiness, nausea, vomiting, and hot and cold flushes. Most of the studies were limited by their small sample sizes.
Authors' conclusions
Since the last version of this review, we identified another study that added another form of medical therapy, BoNTs, specifically BoNT/A, to the list of pharmacologic interventions being reviewed for clinical efficacy in phantom limb pain. However, the results of this study did not substantially change the main conclusions. The short- and long-term effectiveness of BoNT/A, opioids, NMDA receptor antagonists, anticonvulsants, antidepressants, calcitonins, and local anaesthetics for clinically relevant outcomes including pain, function, mood, sleep, quality of life, treatment satisfaction, and adverse events remain unclear. Based on a small study, BoNT/A (versus lidocaine/methylprednisolone) does not decrease phantom limb pain. Morphine, gabapentin, and ketamine demonstrate favourable short-term analgesic efficacy compared with placebo. Memantine and amitriptyline may not be effective for PLP. However, results must be interpreted with caution, as they were based mostly on a small number of studies with limited sample sizes that varied considerably and also lacked long-term efficacy and safety outcomes. The direction of efficacy of calcitonin, local anaesthetics, and dextromethorphan needs further clarification. Overall, the efficacy evidence for the reviewed medications is thus far inconclusive. Larger and more rigorous randomised controlled trials are needed for us to reach more definitive conclusions about which medications would be useful for clinical practice.
219 citations
••
TL;DR: After the preclinical studies which showed that the vaccine was safe and immunogenic in animal models, a pilot phase 1 clinical trial, blind versus placebo, was performed on adult volunteers and the difference between the incidence of adverse reactions associated with vaccine and placebo administration was not statistically significant.
211 citations
Authors
Showing all 4621 results
Name | H-index | Papers | Citations |
---|---|---|---|
Barry M. Popkin | 157 | 751 | 90453 |
Aldo P. Maggioni | 134 | 940 | 90242 |
Michael H. Weisman | 92 | 460 | 39567 |
Johan Ärnlöv | 91 | 386 | 90490 |
Sheila K. West | 89 | 499 | 33719 |
Young Ho Kim | 82 | 2528 | 47681 |
Min Gu | 78 | 729 | 22238 |
Mary L. Marazita | 77 | 436 | 21909 |
Kathleen J. Green | 74 | 193 | 14752 |
Agnes R. Quisumbing | 72 | 311 | 18433 |
Thomas M. Brooks | 71 | 215 | 33724 |
Rigoberto C. Advincula | 65 | 409 | 13632 |
Carl Abelardo T. Antonio | 60 | 106 | 66867 |
Rai S. Kookana | 60 | 281 | 14520 |
J. Kevin Baird | 56 | 185 | 12363 |